Free tool
FAERS Monitor: Trental
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018631 or its brand name (Trental, Pentoxifylline). Reports on generic versions are filed under their own applications.
Reports
5,864
Serious
4,790
82% of reports
Hospitalization
2,322
Death reported
941
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue544
- diarrhoea522
- dyspnoea498
- nausea488
- drug ineffective472
- dizziness466
- asthenia439
- fall426
- headache425
- insomnia375
- arthralgia366
- vomiting356
- pruritus342
- off label use340
- decreased appetite320
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 168 |
| 2005 | 159 |
| 2006 | 160 |
| 2007 | 116 |
| 2008 | 140 |
| 2009 | 176 |
| 2010 | 201 |
| 2011 | 230 |
| 2012 | 288 |
| 2013 | 159 |
| 2014 | 214 |
| 2015 | 217 |
| 2016 | 283 |
| 2017 | 274 |
| 2018 | 358 |
| 2019 | 364 |
| 2020 | 336 |
| 2021 | 383 |
| 2022 | 383 |
| 2023 | 379 |
| 2024 | 366 |
| 2025 | 326 |
| 2026 | 182 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,295 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| insomniaSignal | 375 | 5.1 | 4.6 | 1,230 |
| decreased appetiteSignal | 320 | 4.9 | 4.4 | 1,014 |
| fallSignal | 426 | 4.6 | 4.2 | 1,212 |
| astheniaSignal | 439 | 4.2 | 3.8 | 1,082 |
| dizzinessSignal | 466 | 3.4 | 3.1 | 785 |
| pruritusSignal | 342 | 3.2 | 2.9 | 522 |
| arthralgiaSignal | 366 | 3.2 | 2.9 | 548 |
| dyspnoeaSignal | 498 | 3.2 | 2.9 | 751 |
| diarrhoeaSignal | 522 | 2.9 | 2.7 | 669 |
| vomitingSignal | 356 | 2.7 | 2.5 | 393 |
| fatigueSignal | 544 | 2.5 | 2.3 | 510 |
| headacheSignal | 425 | 2.4 | 2.2 | 368 |
| nauseaSignal | 488 | 2.2 | 2.0 | 335 |
| off label use | 340 | 1.4 | 1.3 | 39 |
| drug ineffective | 472 | 1.3 | 1.2 | 31 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.